Search BBIO
BridgeBio Pharma, Inc.
Nasdaq · CIK 1743881
Last close67.25
Daily change+0.34 (0.51%)
10 Years gain+144.10%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
BBIO · STANDARD
SIC 2834 · Pharmaceutical Preparations · Fiscal year end 1231
Fundamental
50.1Momentum
100.0Acceleration
100.0Confidence
72.0Annual Revenue7
Quarterly Revenue23
Annual CFO9
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth25.0 / 25
Quality18.7 / 25
Capital Efficiency0.0 / 20
Balance Sheet6.4 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
Operating leverageOperating margin improved by 68.1156 percentage points.
Warnings
Inventory anomaly · MEDIUMInventory growth is materially above revenue growth.
Gross margin compression · MEDIUMGross margin compressed by 3.9255 percentage points.
Possible growth trap · HIGHRevenue growth is high, but quality indicators are deteriorating.
Key Metrics
Revenue Growth TTM101.25%OK
Revenue CAGR 3Y86.3%OK
Gross Margin94.74%OK
Operating Margin-73.57%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROICn/aMISSING
Incremental Operating Margin 3Y-5.21%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y2.97%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $502.08M | $481.11M | -$523.41M | -$445.91M | -$447.01M | 95.82% | -104.25% | -89.03% | n/a | 191.53M |
| 2025 FY Dec 31, 2024 | $221.90M | $218.02M | -$592.97M | -$520.73M | -$521.66M | 98.25% | -267.22% | -235.09% | n/a | 186.08M |
| 2025 FY Dec 31, 2023 | $9.30M | $6.86M | -$607.37M | -$527.72M | -$529.03M | 73.71% | -6,528.75% | -5,686.62% | n/a | 162.79M |
| 2024 FY Dec 31, 2022 | $77.65M | $74.21M | -$512.20M | -$419.49M | -$424.32M | 95.58% | -659.65% | -546.46% | n/a | 147.47M |
| 2023 FY Dec 31, 2021 | $69.72M | $66.60M | -$576.63M | -$497.93M | -$511.18M | 95.53% | -827.12% | -733.23% | n/a | 144.36M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $669.46M | sum latest 4 fiscal quarters Revenue | OK | 0001743881-26-000027, 0001743881-25-000012 |
| Revenue Growth TTM | 101.25% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001743881-26-000027, 0001743881-25-000012 |
| Revenue CAGR 3Y | 86.3% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001743881-26-000009 |
| Revenue CAGR 5Y | 127.44% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001743881-26-000009 |
| Gross Profit CAGR 3Y | 86.46% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001743881-26-000009 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001743881-26-000027, 0001743881-25-000012 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 94.74% | Gross Profit / Revenue | OK | 0001743881-26-000027, 0001743881-25-000012 |
| Operating Margin | -73.57% | Operating Income / Revenue | OK | 0001743881-26-000027, 0001743881-25-000012 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001743881-26-000027 |
| Current Ratio | 1.23x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 0.27x | (Cash + Short-term Investments) / Total Debt | OK | 0001743881-26-000027 |
| Revenue per Diluted Share | $3.42 | Revenue / Diluted Shares | OK | 0001743881-26-000027, 0001743881-25-000012 |
| SBC / FCF | n/a | SBC / FCF | NOT_MEANINGFUL | derived |